CB708 is a Potent CD73 Inhibitor in Full Human Plasma

**Figure 39.**

**Panel A**

- Human-Recombinant CD73: 0.17
- Human Plasma CD73: 0.36
- Human Cell Surface CD73: 0.21

**Panel B**

- Human CD73

**Panel C**

- Human Plasma CD73

**Panel D**

- Human CD73 Cell Surface

CB708 is Selective for CD73

**Figure 70.**

**Panel A**

- CB708

**Panel B**

- Human CD73

**Panel C**

- Human Plasma CD73

**Panel D**

- Human CD73 Cell Surface

CB708 has Oral Exposure and Pharmacodynamic Effect

**Figure 40.**

**Panel A**

- CB708 Plasma PK

**Panel B**

- Mouse Plasma CD73

**Panel C**

- CB708 Tumor PK

CB708 Activates a Tumor-Directed Immune Response

**Figure 41.**

**Panel A**

- Vehicle

**Panel B**

- Vehicle anti-CD8

**Panel C**

- Vehicle anti-CD20

CB708 Inhibits CD73 in Patient Serum

**Figure 42.**

**Panel A**

- Vehicle

**Panel B**

- Vehicle anti-CD8

**Panel C**

- Vehicle anti-CD20

CB708 Enhances the Efficacy of IO and Chemotherapy Agents

**Figure 43.**

**Panel A**

- Vehicle

**Panel B**

- Vehicle anti-CD8

**Panel C**

- Vehicle anti-CD20

Conclusion

CB708 is an orally bioavailable and selective CD73 inhibitor with micromolar potency.

Adenosine-mediated suppression of CD73 by T cell function and proliferation is reversed by CB708.

CB708 has good exposure in animals, is well-tolerated, and shows pharmacodynamic effect.

Anti-tumor single-agent activity of CB708 is immune-mediated.

CB708 enhances the anti-tumor effect of checkpoint blockade and chemotherapy.

CB708 is expected to enter clinical development in 2019.